Skip to content

Evaluation of Wound Dressings in the Reduction of Shear- Force

Evaluation of Wound Dressings to Reduce the Harmful Effects of Shear- Force at the Skin

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02348671
Enrollment
10
Registered
2015-01-28
Start date
2015-03-31
Completion date
2015-07-31
Last updated
2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Ulcer

Brief summary

The purpose of this study is to investigate if wound dressings are capable in reducing the effects of shear- force at the skin. With our own shear- force model we are able to apply 19 Newton shear- force combined with 9 newton pressure at the skin of the non- dominant forearm. After half an hour we measure IL-1alpha/ total protein- ratio, cutaneous blood flow (Laser doppler, Moor LDI) and the erythema index (DSMIIColormeter) which occurs as an effect of shear- force application at the skin. Then, we apply 19 Newton shear- force combined with 9 Newton pressure at the dominant fore-arm but this time we put a wound dressing between the skin and shear- force model. After half an hour we measure the IL-1alpha/total protein-ratio, cutaneous blood flow and the erythema index. This research consists of three research day, each day we are going to investigate a different wound dressing

Interventions

OTHERshear- force

19 Newton shear- force and 3,9 kPa pressure for half an hour

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* healhty volunteer * age 18- 30 * BMI 20- 30

Exclusion criteria

* Trauma fore-arms * Diabetes mellitus type I or type II * The use of NSAID's in the last 7 days * Vascular diseases * Muscular dystrophy * Malignancy * Participant is unable to give informed consent

Design outcomes

Primary

MeasureTime frame
Cutaneous blood flow, erythema index, IL-1alpha/Total protein ratioDirectly after intevention

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026